Skip to main content
. Author manuscript; available in PMC: 2011 Oct 15.
Published in final edited form as: Cancer Res. 2006 Feb 1;66(3):1500–1508. doi: 10.1158/0008-5472.CAN-05-2925

Figure 2.

Figure 2

mTOR inhibition activates Akt in humans. A, liver metastasis of a colorectal carcinoma from a patient treated with a daily administration of RAD001 for 4 weeks. pAkt was expressed in nuclei and cytoplasm of tumor cells (1) and levels of expression increased after therapy (2). Skin infiltration by ductal carcinoma in a patient treated with a weekly administration of RAD001 for 4 weeks. A similar increment of pAkt was observed before (3) and after therapy (4); (3,3′-diaminobenzidine, pAkt ×400). B, evaluation of levels of pAkt in paired tumor samples from patients treated with daily and weekly administration of RAD001 by immunohistochemistry. A significant increment (P = 0.018) of this protein was observed in eight patients. C, tumor and biopsy characteristics. The characteristics of each tumor biopsy and the dose schedule of the eight patients in the RAD001 clinical trial are described.